MANA 312
Alternative Names: MANA-312Latest Information Update: 28 Jan 2024
At a glance
- Originator Mana Therapeutics
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (IV, Infusion)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Second-line therapy or greater) in USA (IV, Infusion)
- 28 Mar 2023 Mana Therapeutics terminates a phase I trial in Acute myeloid leukaemia and/or Myelodysplastic syndromes (Second-line therapy or greater) in USA (IV) due to product manufacturing (NCT04679194)